Latest updates
-
In the press, Awards
Exonate Shortlisted for Biotech Company of the Year by The Cambridge Independent Science and Technology Awards.
-
In the press, Company news
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
- Insights Biotech Showcase, San Francisco 2024
- In the press Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema
- Insights Exonate at Biotrinity 2022
- Company news Exonate at Biotrinity 2021
- Insights Exonate announces involvement in exciting STEM outreach project.
- In the press Exonate announces the initiation of Phase Ib/II clinical trial for Diabetic Macular Oedema, as part of its collaboration with Janssen